Scarica l'app Stockscreener
5.08
4.87%
-0.26
Dopo l'orario di chiusura:
4.99
-0.09
-1.77%
Precedente Chiudi:
$5.34
Aprire:
$5.33
Volume 24 ore:
4.71M
Relative Volume:
0.82
Capitalizzazione di mercato:
$1.39B
Reddito:
$8.10M
Utile/perdita netta:
$-92.72M
Rapporto P/E:
-14.94
EPS:
-0.34
Flusso di cassa netto:
$-82.52M
1 W Prestazione:
+1.60%
1M Prestazione:
+78.87%
6M Prestazione:
+330.51%
1 anno Prestazione:
+150.25%
Intervallo 1D:
$4.8701
$5.39
Intervallo di 1 settimana:
$4.70
$5.5082
Portata 52W:
$1.05
$5.5082
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Nome
Taysha Gene Therapies Inc
Settore
Industria
Telefono
(214) 612-0000
Indirizzo
3000 PEGASUS PARK DRIVE, DALLAS
Confronta TSHA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
5.08 | 1.41B | 8.10M | -92.72M | -82.52M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-11 | Iniziato | BofA Securities | Buy |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-04-09 | Iniziato | Piper Sandler | Overweight |
| 2023-02-01 | Downgrade | Jefferies | Buy → Hold |
| 2023-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Downgrade | Goldman | Buy → Neutral |
| 2022-03-09 | Iniziato | Robert W. Baird | Outperform |
| 2022-03-01 | Iniziato | Wells Fargo | Overweight |
| 2022-02-18 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-16 | Iniziato | Guggenheim | Buy |
| 2021-07-16 | Iniziato | Needham | Buy |
| 2021-06-24 | Iniziato | Truist | Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-06-09 | Iniziato | Wedbush | Outperform |
| 2021-06-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Ripresa | Jefferies | Buy |
| 2021-02-24 | Iniziato | William Blair | Outperform |
| 2021-01-05 | Iniziato | Oppenheimer | Outperform |
| 2020-10-19 | Iniziato | Chardan Capital Markets | Buy |
| 2020-10-19 | Iniziato | Goldman | Buy |
| 2020-10-19 | Iniziato | Jefferies | Buy |
| 2020-10-19 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie
Why Taysha Gene Therapies Inc. stock is favored by top institutionsJuly 2025 Trends & Community Verified Trade Signals - newser.com
Taysha regains full rights to Rett syndrome gene therapy program By Investing.com - Investing.com South Africa
Taysha (TSHA) Reclaims Full Rights to Key Rett Syndrome Program - GuruFocus
Taysha Gene Therapies Regains Full Rights to TSHA-102 Program - TradingView
Why Taysha Gene Therapies Inc. is moving todayJuly 2025 Big Picture & AI Based Buy/Sell Signal Reports - newser.com
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 - GlobeNewswire
Taysha Regains Full Rights to TSHA-102; 100% Part A Response | TSHA Stock News - Stock Titan
Taysha Gene Therapies stock hits 52-week high at $5.41 By Investing.com - Investing.com Nigeria
Earnings visualization tools for Taysha Gene Therapies Inc.Quarterly Trade Summary & Advanced Swing Trade Entry Alerts - newser.com
Tick level data insight on Taysha Gene Therapies Inc. volatilityJuly 2025 Sector Moves & Safe Entry Point Alerts - newser.com
Taysha Gene Therapies stock hits 52-week high at $5.41 - Investing.com
Taysha Gene Therapies stock rating reiterated at Market Outperform by Citizens - Investing.com Canada
Has Taysha Gene Therapies Inc. formed a bullish divergenceJuly 2025 Decliners & Low Drawdown Investment Strategies - newser.com
Collegium Pharmaceutical, Inc. (COLL): A Bull Case Theory - MSN
What MACD and RSI say about Taysha Gene Therapies Inc.2025 Volume Leaders & Smart Allocation Stock Tips - newser.com
Can Taysha Gene Therapies Inc. stock hit record highs again2025 Volatility Report & Verified Entry Point Signals - newser.com
Is Taysha Gene Therapies Inc. trending in predictive chart modelsPortfolio Return Report & Consistent Income Trade Ideas - newser.com
Weiss Ratings Reiterates Sell (D-) Rating for Taysha Gene Therapies (NASDAQ:TSHA) - MarketBeat
Taysha Gene Therapies Hits Day High with 7.2% Surge in Stock Price - Markets Mojo
Taysha Gene Therapies (TSHA) Reveals Enhanced Trial Results for Rett Syndrome - GuruFocus
Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting - The Manila Times
Taysha Gene Therapies Presents New Supplemental Data - GlobeNewswire
Taysha's TSHA-102 Shows 100% Response in Phase 1/2 Rett Trial | TSHA Stock News - Stock Titan
Will Taysha Gene Therapies Inc. stock continue dividend increasesMarket Sentiment Summary & Technical Entry and Exit Tips - newser.com
Analyzing net buyer seller activity in Taysha Gene Therapies Inc.Weekly Trade Analysis & Growth Oriented Trading Recommendations - newser.com
Visual analytics tools that track Taysha Gene Therapies Inc. performanceEarnings Beat & Daily Technical Stock Forecast Reports - newser.com
Taysha Gene Therapies Hits Day Low of $4.40 Amid Price Pressure - Markets Mojo
Taysha Gene Therapies, Inc. Sees Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Taysha soars on FDA breakthrough therapy status for lead asset - MSN
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 4.9%Time to Sell? - MarketBeat
Taysha Gene Therapies Hits New 52-Week High at $5.40 - Markets Mojo
Taysha Gene Therapies: Breakthrough Rett Program With BLA Acceleration Potential (TSHA) - Seeking Alpha
Will Taysha Gene Therapies Inc. stock maintain growth story2025 Trading Volume Trends & Fast Moving Market Watchlists - newser.com
How to interpret RSI for Taysha Gene Therapies Inc. stockWeekly Trade Analysis & Low Volatility Stock Recommendations - newser.com
Taysha Snags FDA Breakthrough Therapy Designation for Rett Syndrome Gene Therapy TSHA-102 - CGTLive®
How Recent Developments Are Rewriting the Story for Taysha Gene Therapies - Yahoo Finance
Taysha Gene Therapies (TSHA) Gets a Buy from Canaccord Genuity - The Globe and Mail
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Needham & Company LLC Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock Price - Defense World
Best Small Cap Stocks To Add to Your Watchlist – October 2nd - Defense World
Taysha Gene Therapies Inc Azioni (TSHA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Taysha Gene Therapies Inc Azioni (TSHA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Nagendran Sukumar | President and Head of R&D |
Sep 10 '25 |
Option Exercise |
0.70 |
41,150 |
28,760 |
1,206,439 |
| Nagendran Sukumar | President and Head of R&D |
Sep 10 '25 |
Sale |
3.23 |
200,000 |
646,000 |
1,006,439 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):